<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655822</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-444-001</org_study_id>
    <nct_id>NCT02655822</nct_id>
  </id_info>
  <brief_title>Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers</brief_title>
  <official_title>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corvus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral
      small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the
      immune system. This trial will study the safety, tolerability, and anti-tumor activity of
      ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor
      against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor.
      Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral
      small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the
      immune system. This trial will study the safety, tolerability, and anti-tumor activity of
      ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1
      inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine
      suppresses the anti-tumor activity of T cells and other immune cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>28 days following first administration of ciforadenant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate per RECIST v1.1 criteria of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>From start of treatment to end of treatment, up to 72 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of ciforadenant as a single agent and in combination with atezolizumab</measure>
    <time_frame>Continuously, up to 72 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Area under the curve (AUC) of ciforadenant</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and median Maximum concentration (Cmax) of ciforadenant</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the MDL (maximum dose level) of single agent ciforadenant</measure>
    <time_frame>From start of treatment to end of treatment, up to 72 months.</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Renal Cell Cancer</condition>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant + atezolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciforadenant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>100 mg orally twice daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 1 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>100 mg orally twice daily for 28 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 2 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>200 mg orally once daily for the first 14 days of each 28-day cycle.</description>
    <arm_group_label>Cohort 3 - Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant + atezolizumab</intervention_name>
    <description>Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciforadenant</intervention_name>
    <description>Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.</description>
    <arm_group_label>Cohort 5 - Closed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Renal Cell Carcinoma Inclusion Criteria

          1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          2. Documented pathologic diagnosis of clear cell RCC.

          3. Relapsed or refractory to 1-2 prior lines of therapy containing at least an
             anti-PD-(L)1 agent.

          4. Measurable disease according to RECIST v1.1

          5. Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.

        Renal Cell Carcinoma Exclusion Criteria

          1. History of severe hypersensitivity reaction to monoclonal antibodies.

          2. Has immunodeficiency or requires treatment with systemic immunosuppressive medication
             within 2 weeks prior to initiation of study treatment or anticipation of need for
             systemic immunosuppressant medication during study treatment.

          3. Has an active autoimmune disease requiring systemic treatment with in the past 2 years
             OR a documented history of clinically severe autoimmune disease.

        Metastatic Castration-Resistant Prostate Cancer Inclusion Criteria

          1. Documentation of disease: progressive CRPC with histologically or cytologically
             confirmed adenocarcinoma of the prostate.

          2. Patients must have radiologically evident metastatic disease, but it can be measurable
             or non-measurable disease:

               -  Measurable disease: nodal, visceral, or extra nodal lesions according to RECIST
                  v1.1 using a diagnostic computed tomography

               -  Non-measurable disease: bone only disease (up to 1/3 of study population) per
                  PCWG3 criteria

          3. 1-3 prior lines of therapy, including at least one newer generation androgen synthesis
             inhibitor (e.g., abiraterone) or androgen receptor antagonist (e.g., enzalutamide,
             apalutamide, darolutamide).

          4. Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

        Metastatic Castration-Resistant Prostate Cancer Exclusion Criteria

          1. Has pure small-cell histology and variants with predominant (â‰¥ 50%) neuroendocrine
             differentiation.

          2. Has a history of severe hypersensitivity reaction to monoclonal antibodies.

          3. Has immunodeficiency or requires treatment with systemic immunosuppressive medication
             within 2 weeks prior to initiation of study treatment or anticipation of need for
             systemic immunosuppressant medication during study treatment.

          4. Has an active autoimmune disease requiring systemic treatment with in the past 2 years
             OR a documented history of clinically severe autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehrdad Mobasher, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Corvus Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>650-900-4520</phone>
    <email>inquiry@corvuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-694-2873</phone>
    </contact>
    <investigator>
      <last_name>Alejandro Recio-Boiles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-444-2559</phone>
    </contact>
    <investigator>
      <last_name>Lawrence Fong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-723-2300</phone>
    </contact>
    <investigator>
      <last_name>Sukhmani Padda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-785-4095</phone>
    </contact>
    <investigator>
      <last_name>Mario Sznol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-2223</phone>
    </contact>
    <investigator>
      <last_name>Stephen Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-243-1000</phone>
    </contact>
    <investigator>
      <last_name>Jaime R Merchan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-1900</phone>
    </contact>
    <investigator>
      <last_name>Taofeek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-942-5000</phone>
    </contact>
    <investigator>
      <last_name>Philip Bonomi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>855-702-8222</phone>
    </contact>
    <investigator>
      <last_name>Mark Ratain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-955-5222</phone>
    </contact>
    <investigator>
      <last_name>Patrick Forde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-726-2000</phone>
    </contact>
    <investigator>
      <last_name>Rebecca Heist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-527-6266</phone>
    </contact>
    <investigator>
      <last_name>Elisabeth Heath, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-275-7724</phone>
      <email>askrpci@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Saby George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-659-5600</phone>
    </contact>
    <investigator>
      <last_name>Joshua Brody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>sm3011@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Carvajal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-525-2225</phone>
    </contact>
    <investigator>
      <last_name>Martin Voss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-647-2811</phone>
    </contact>
    <investigator>
      <last_name>Leonard Appleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>972-566-3000</phone>
    </contact>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>414-805-8200</phone>
    </contact>
    <investigator>
      <last_name>Matthew Riese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 7 3646 8111</phone>
    </contact>
    <investigator>
      <last_name>Brett Hughes, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>(03) 9594 6666</phone>
    </contact>
    <investigator>
      <last_name>Daphne Day, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1 780-432-8771</phone>
    </contact>
    <investigator>
      <last_name>Michael Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1 604-877-6000</phone>
    </contact>
    <investigator>
      <last_name>Daniel Renouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>613-761-4295</phone>
    </contact>
    <investigator>
      <last_name>Rachel Goodwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>mCRPC</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

